HCM
VRTX icon

Howland Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Howland Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$982K Buy
1,977
+2
+0.1% +$886 0.04% 164
2026
Q1 		$882K Buy
1,975
+96
+5% +$44.8K 0.03% 158
2025
Q4 		$852K Sell
1,879
-39
-2% -$16.8K 0.03% 161
2025
Q3 		$751K Buy
1,918
+142
+8% +$59.3K 0.03% 170
2025
Q2 		$791K Sell
1,776
-199
-10% -$91.7K 0.03% 168
2025
Q1 		$958K Buy
1,975
+250
+14% +$117K 0.04% 151
2024
Q4 		$695K Buy
1,725
+39
+2% +$18.1K 0.03% 177
2024
Q3 		$784K Buy
1,686
+197
+13% +$94.6K 0.03% 168
2024
Q2 		$698K Buy
1,489
+653
+78% +$283K 0.03% 167
2024
Q1 		$349K Sell
836
-137
-14% -$57.9K 0.02% 216
2023
Q4 		$396K Sell
973
-48
-5% -$17.7K 0.02% 203
2023
Q3 		$355K Sell
1,021
-125
-11% -$43.7K 0.02% 202
2023
Q2 		$403K Hold
1,146
– – 0.02% 202
2023
Q1 		$361K Buy
+1,146
New +$344K 0.02% 206

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Howland Capital Management's VRTX Position: Q2 2026 in Review

Howland Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.1% in Q2 2026, buying an estimated $886 and bringing the position to 1,977 shares worth $982K. The position accounts for 0.04% of the portfolio, ranked #164.

Howland Capital Management first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Howland Capital Management held 1,977 shares of Vertex Pharmaceuticals worth $982K as of Q2 2026.
  • Howland Capital Management bought 2 Vertex Pharmaceuticals shares in Q2 2026, an estimated $886.
  • Vertex Pharmaceuticals made up 0.04% of Howland Capital Management's portfolio in Q2 2026, its #164 holding.
  • Howland Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Howland Capital Management's 13F filing for Q2 2026, filed 13 Jul 2026.